Evidence map›Paper›PMID 40476847›Full record

ArticleAntimicrobial agents and chemotherapy2025

Pharmacokinetics of nikkomycin Z following multiple doses in healthy subjects.

David E Nix, Susan E Hoover, Nathan J Hanan, John Galgiani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

David E NixDepartment of Pharmacy Practice & Science, R. Ken Coit College of Pharmacy, University of Arizona, Tucson, Arizona, USA.ORCID 0000-0002-9440-465X
Susan E HooverDepartment of Medicine, University of South Dakota, Sioux Falls, South Dakota, USA.
Nathan J HananClinical Pharmacology Modeling and Simulation, Glaxo Smith-Kline, Collegeville, Pennsylvania, USA.
John GalgianiValley Fever Center for Excellence, Department of Medicine, Department of Immunobiology, College of Medicine-Tucson, and BIO5 Institute, University of Arizona, Tucson, Arizona, USA.ORCID 0000-0002-7882-1883

Funding

Nikkomycin Z Treatment for CoccidioidomycosisR34AI072320 · NIAID · UNIVERSITY OF ARIZONA · PI GALGIANI, JOHN N · 2006 to 2006
$225k
FDA HHS R01 FD003347FDA Office of Orphan Product Development 1R01FD003347JT Tai & Company Foundation Inc.NIAID NIH HHS R34 AI072320NIH/NIAID 1R34AI072320-01
6 · The paper itself

Abstract

Nikkomycin Z is an investigational antifungal agent that inhibits chitin synthesis. The drug shows promise against endemic fungi such as

Indexed as

AminoglycosidesAntifungal AgentsAdministration, OralAdolescentAdultArea Under CurveFemaleHealthy VolunteersHumansMaleMiddle AgedYoung AdultAminoglycosidesAntifungal Agentsnikkomycinantifungalchitin synthaseCoccidioidesnikkomycin Zpharmacokinetics

Identifiers

PMID40476847
PMCPMC12217460

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.